Overview

Thromboprophylaxis in Critically Ill Patients

Status:
Terminated

Trial end date:
2005-04-01

Target enrollment:
0

Participant gender:
All

Summary

Intensive care patients are at high risk to develop deep venous thrombosis and pulmonary embolism. Despite anticoagulation with heparin 7% of ICU patients suffer from this serious complication. Optimal regimens for prevention of VTE have been established in medical patients only and are not known for ICU patients. It was therefore the aim of this study to compare the bioavailability of a low molecular weight heparin in ICU patients and in medical patients. Furthermore, we looked wether a 50% dose increase resulted in better bioavailability of this drug.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Medical University of Vienna

Treatments:

Dalteparin
Heparin, Low-Molecular-Weight
Tinzaparin

Criteria

Inclusion Criteria:

- Requirement for prophylactic anticoagulation, patient age ³19 years, creatinine
clearance within normal range, prothrombin time >30% and thrombocyte counts >100 G/l.

Exclusion Criteria:

- Estimated time of admission less than 24 hours, full anticoagulation, renal failure,
history of heparin-induced thrombocytopenia, hereditary or acquired coagulation
disorders.